Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.97 USD
Change Today -0.03 / -0.14%
Volume 517.2K
MNTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Announces Executive Changes

Momenta Pharmaceuticals Inc. announced that Rick Shea has advised the company of his intention to step down as Chief Financial Officer (CFO) once a successor is identified and appointed. Mr. Shea will remain with the company to assist with the CFO succession and serve in a newly created role of Senior Vice President, Corporate Communications and Operations for a transition period prior to his planned retirement in 2016. Momenta has initiated a CFO search. Mr. Shea joined Momenta in October 2003 as Chief Financial Officer and Senior Vice President.

Momenta Pharmaceuticals, Inc. Announces Launch of Glatopa (Glatiramer Acetate Injection)

Momenta Pharmaceuticals Inc. announced that Sandoz has initiated its U.S. launch of once daily Glatopa (glatiramer acetate injection), a generic equivalent of daily COPAXONE 20 mg, developed under a collaboration agreement between Momenta and Sandoz. Glatopa is the first AP-rated substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Under the terms of its collaboration agreement with Sandoz, Momenta will receive a $10.0 million milestone payment upon first commercial sale. Momenta is also eligible to receive up to $120 million in remaining milestone payments upon the achievement of certain U.S. commercial and sales-based milestones for the Glatopa Glatopa was determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, with the same active ingredients, route of administration, strength and dosage form. Glatopa's high quality U.S.-based supply chain and manufacturing process meet rigid FDA standards, and Glatopa is fully substitutable at the pharmacy level. Sandoz has also introduced a patient support service offering that includes financial support to eligible patients, personalised injection training and 24-hour access to nurses to answer non-clinical questions.

Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE 20 mg Suit

Momenta Pharmaceuticals Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has again found that U.S. patent No. 5,800,808, related to a method of manufacturing glatiramer acetate, is invalid as indefinite.

Momenta Pharmaceuticals to Present New Data from Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer

Momenta Pharmaceuticals Inc. will present updated data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane®) and gemcitabine (GEM) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2015 ASCO Annual Meeting on June 1, 2015 from 8:00 to 11:30 am CDT (Abstract #4114). Necuparanib was administered daily in combination with 125 mg/m2 nabP and 1000 mg/m2 GEM (Days 1, 8, and 15 of each 28-day cycle). The necuparanib starting dose was 0.5 mg/kg, which was increased via a modified 3+3 design until a maximum tolerated dose (MTD) was determined. nabP was added to the treatment regimen starting with Cohort 3. Thirty-nine patients (12 patients in the first two cohorts and 27 patients in the five subsequent cohorts) received necuparanib and were included in the analyses.

Momenta Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM

Momenta Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Richard P. Shea, Chief Financial Officer, Senior Vice President and Treasurer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $21.97 USD -0.03

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $2.16 USD 0.00
Amphastar Pharmaceuticals Inc $16.81 USD +0.26
OraSure Technologies Inc $4.89 USD -0.15
SciClone Pharmaceuticals Inc $9.55 USD -0.12
Sucampo Pharmaceuticals Inc $21.64 USD -0.46
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.0x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.